Song NP, Zhen XW, Li LD, et al. - Researchers undertook this prospective analysis to clarify the link of plasma calprotectin with platelet activation and no-reflow phenomenon in acute coronary syndrome (ACS). Participants were 176 Chinese patients (mean age was 64(±11) years) with ACS who had received percutaneous coronary interventions (PCIs). The definition of angiographic no-reflow was thrombolysis in myocardial infarction grade less than 3. A total of 22 patients were found to have no-reflow during the PCI procedures and the prevalence was estimated to be 12.5%. In this study, plasma calprotectin was not only identified to be related to platelet activation but also was suggested to possibly be an early predictive biomarker of no-reflow in patients suffering from ACS.